<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109758</url>
  </required_header>
  <id_info>
    <org_study_id>S282.1.002</org_study_id>
    <secondary_id>2007-006147-52</secondary_id>
    <nct_id>NCT01109758</nct_id>
  </id_info>
  <brief_title>Effects of Fenofibrate on Gene Expression in Healthy Volunteers</brief_title>
  <official_title>Effects of Fenofibrate on Gene Expression Activity and DNA Methylation Profile in Circulating Monocytes of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how fenofibrate modify gene expression in circulating&#xD;
      monocytes of healthy volunteers after 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of gene activity of markers in circulating monocytes between Baseline and 6 weeks of fenofibrate treatment</measure>
    <time_frame>Between Baseline and 6 weeks</time_frame>
    <description>The calculation is the difference between the gene expression intensity after 6 weeks of treatment and the gene expression intensity at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA methylation pattern</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid levels</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary protein profile</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female,&#xD;
&#xD;
          -  To be aged 40-65 years,&#xD;
&#xD;
          -  To be post menopausal female not receiving hormone replacement therapy,&#xD;
&#xD;
          -  To have normal homocysteine, folate and vitamin B12 levels at baseline (results&#xD;
             available for initiation of treatment),&#xD;
&#xD;
          -  To be in good health as determined by medical history, physical examination, ECG,&#xD;
             vital signs, serum/urine biochemistry and hematology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with clinically relevant evidence of cardiovascular,&#xD;
             gastrointestinal/hepatic, renal, neurologic/psychiatric or emotional, respiratory,&#xD;
             urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat),&#xD;
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, drug&#xD;
             hypersensitivity, (drug) allergy, endocrine, major surgery or other relevant diseases&#xD;
             as revealed by medical history, physical examination, and laboratory assessments which&#xD;
             may interfere with the absorption, distribution, metabolism or elimination of drugs or&#xD;
             constitute a risk factor when taking the study medication,&#xD;
&#xD;
          -  Subjects who have been treated with fenofibrate in a previous study,&#xD;
&#xD;
          -  Subjects who have taken a single dose of an investigational drug within 30 days or&#xD;
             multiple doses of any investigational drug within 60 days prior to dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Claire Nee</name_title>
    <organization>Solvay Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Fenofibrate</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>DNA methylation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

